

National Stock Exchange of India

Circular

Department: Listing	
Download Ref No: NSE/CML/54903	Date: December 19, 2022
Circular Ref. No: 1528/2022	

To All Members,

Sub: Suspension of trading in securities

Pursuant to the provisions of SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 (“SOP”) with respect to Standard Operating Procedure for suspension and revocation of trading of shares of listed entities for non-compliance with certain regulations of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 (“Listing Regulations”), it is hereby informed that the following Company have not complied with requirements of Regulation 34 (i.e. Submission of Annual Reports) of the Listing Regulations for two consecutive years i.e. March 31, 2022 and March 31, 2021. Hence, the trading in securities of below named company shall be suspended w.e.f. January 19, 2022. Details are as under:

Sr. No.	Symbol	Name of Company
1	VIVIMEDLAB	Vivimed Labs Limited

Further, if the above-mentioned company do not comply as per the provisions of SOP Circular on or before **January 16, 2023**, then:

- Trading in securities of the above Company would be suspended w.e.f. January 19, 2023, and the suspension will continue till such time the Company comply with SOP Circular.
- After 15 days of suspension, trading in the securities of non-compliant Company would be allowed on Trade for Trade basis in (Z category) on the first trading day of every week for six months.

For and on behalf of
National Stock Exchange of India Limited

Ravi Shekhar Rai
Manager